{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:25:32Z","timestamp":1762507532914},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.lpm.2018.09.001","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T23:39:28Z","timestamp":1538177968000},"page":"746-756","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enjeux li\u00e9s \u00e0 l\u2019hyperthyro\u00efdie induite par l\u2019amiodarone"],"prefix":"10.1016","volume":"47","author":[{"given":"Igor","family":"Tauveron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Batisse-Lignier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwan","family":"Maqdasy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2018.09.001_bib0395","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/01.CIR.93.12.2128","article-title":"Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators","volume":"93","author":"Massie","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2018.09.001_bib0400","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1056\/NEJMoa013029","article-title":"Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation","volume":"346","author":"Dorian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.09.001_bib0405","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMct065916","article-title":"Amiodarone for atrial fibrillation","volume":"356","author":"Zimetbaum","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2018.09.001_bib0410","first-page":"465","article-title":"Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia","volume":"6","author":"Van Herendael","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.lpm.2018.09.001_bib0415","first-page":"240","article-title":"The effects of amiodarone on the thyroid","volume":"22","author":"Martino","year":"2001","journal-title":"Endocr Rev"},{"key":"10.1016\/j.lpm.2018.09.001_bib0420","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1210\/jc.2010-0180","article-title":"Approach to the patient with amiodarone-induced thyrotoxicosis","volume":"95","author":"Bogazzi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0425","first-page":"121","article-title":"Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy","volume":"79","author":"Newman","year":"1998","journal-title":"Heart Br Card Soc"},{"key":"10.1016\/j.lpm.2018.09.001_bib0430","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2265.2004.02119.x","article-title":"Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association","volume":"61","author":"Bartalena","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2018.09.001_bib0435","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1365-2265.2008.03268.x","article-title":"Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists","volume":"69","author":"Tanda","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2018.09.001_bib0440","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1365-2265.2011.04087.x","article-title":"Determinants and outcome of amiodarone-associated thyroid dysfunction","volume":"75","author":"Ahmed","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2018.09.001_bib0445","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2265.2007.02920.x","article-title":"Proportion of type 1\u00a0and type 2\u00a0amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy","volume":"67","author":"Bogazzi","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2018.09.001_bib0450","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2007.02.054","article-title":"Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome","volume":"49","author":"Conen","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2018.09.001_bib0455","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1210\/jc.2008-1907","article-title":"Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome","volume":"94","author":"Yiu","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0460","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1210\/jcem.86.1.7119","volume":"86","author":"Daniels","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0465","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/circ.105.11.1275","article-title":"Successful treatment of amiodarone-induced thyrotoxicosis","volume":"105","author":"Osman","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2018.09.001_bib0470","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/hrt.72.3.266","article-title":"Two cases of amiodarone-induced thyrotoxicosis successfully treated with a short course of antithyroid drugs while amiodarone was continued","volume":"72","author":"Trip","year":"1994","journal-title":"Br Heart J"},{"key":"10.1016\/j.lpm.2018.09.001_bib0475","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1210\/jc.2011-1678","article-title":"Continuation of amiodarone delays restoration of euthyroidism in patients with type 2\u00a0amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study","volume":"96","author":"Bogazzi","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0480","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.amjmed.2003.09.036","article-title":"Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis","volume":"116","author":"Hermida","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2018.09.001_bib0485","first-page":"207","article-title":"Prevention of recurrent amiodarone-induced hyperthyroidism by iodine-131","volume":"97","author":"Hermida","year":"2004","journal-title":"Arch Mal Coeur Vaiss"},{"key":"10.1016\/j.lpm.2018.09.001_bib0490","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.amjcard.2016.01.003","article-title":"Amiodarone-induced thyrotoxicosis recurrence after amiodarone reintroduction","volume":"117","author":"Maqdasy","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2018.09.001_bib0495","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/0002-8703(83)90006-6","article-title":"Amiodarone pharmacokinetics","volume":"106","author":"Holt","year":"1983","journal-title":"Am Heart J"},{"key":"10.1016\/j.lpm.2018.09.001_bib0500","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nrendo.2009.225","article-title":"Effects of amiodarone therapy on thyroid function","volume":"6","author":"Cohen-Lehman","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.lpm.2018.09.001_bib0505","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0002-9343(91)90187-3","article-title":"Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism","volume":"91","author":"Trip","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.lpm.2018.09.001_bib0510","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/jcem-62-3-563","article-title":"Iodine kinetic studies during amiodarone treatment","volume":"62","author":"Rao","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0515","first-page":"814","article-title":"Autoregulation of the thyroid. Response to iodide excess and depletion","volume":"47","author":"Ingbar","year":"1972","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.lpm.2018.09.001_bib0520","doi-asserted-by":"crossref","DOI":"10.1210\/jcem-55-6-1058","article-title":"Are selective increases in serum thyroxine (T4) due to iodinated inhibitors of T4\u00a0monodeiodination indicative of hyperthyroidism?","volume":"55","author":"Lambert","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0525","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1210\/endo-45-5-504","article-title":"The temporary nature of the inhibitory action of excess iodine on organic iodine synthesis in the normal thyroid","volume":"45","author":"Wolff","year":"1949","journal-title":"Endocrinology"},{"key":"10.1016\/j.lpm.2018.09.001_bib0530","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/thy.1998.8.83","article-title":"Iodine-induced hyperthyroidism: occurrence and epidemiology","volume":"8","author":"Stanbury","year":"1998","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.lpm.2018.09.001_bib0535","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1210\/endo-113-4-1464","article-title":"The effects of amiodarone on serum thyroid hormones and hepatic thyroxine 5\u2019-monodeiodination in rats","volume":"113","author":"Sogol","year":"1983","journal-title":"Endocrinology"},{"key":"10.1016\/j.lpm.2018.09.001_bib0540","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1172\/JCI108466","article-title":"Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones","volume":"58","author":"Burger","year":"1976","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lpm.2018.09.001_bib0545","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1210\/jcem-53-5-997","article-title":"Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration","volume":"53","author":"Melmed","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0550","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-2007-1004857","article-title":"Amiodarone reduces the effect of T3\u00a0on beta adrenergic receptor density in rat heart","volume":"22","author":"Hartong","year":"1990","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0555","first-page":"192","article-title":"Hyperthyroidism as a possible complication of the treatment of ischemic heart disease with amiodarone","volume":"28","author":"Jonckheer","year":"1973","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.lpm.2018.09.001_bib0560","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/105072501300176471","article-title":"The various effects of amiodarone on thyroid function","volume":"11","author":"Bogazzi","year":"2001","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.lpm.2018.09.001_bib0565","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/eje.1.02122","article-title":"Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality","volume":"154","author":"O'Sullivan","year":"2006","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"key":"10.1016\/j.lpm.2018.09.001_bib0570","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-14-0267","article-title":"The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type","volume":"171","author":"Tomisti","year":"2014","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"key":"10.1016\/j.lpm.2018.09.001_bib0575","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.0300-0664.2001.01458.x","article-title":"Amiodarone-induced thyrotoxicosis: a difficult diagnostic and therapeutic challenge","volume":"56","author":"Bartalena","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2018.09.001_bib0580","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/thy.1997.7.541","article-title":"Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis","volume":"7","author":"Bogazzi","year":"1997","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.lpm.2018.09.001_bib0585","first-page":"770","article-title":"The Midwestern American \u201cepidemic\u201d of iodine-induced hyperthyroidism in the 1920s","volume":"52","author":"Kohn","year":"1976","journal-title":"Bull N Y Acad Med"},{"key":"10.1016\/j.lpm.2018.09.001_bib0590","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.0300-0664.2001.01457.x","article-title":"Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography","volume":"56","author":"Eaton","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2018.09.001_bib0595","first-page":"1402","article-title":"Twenty-four hour radioactive iodine uptake in 35\u00a0patients with amiodarone associated thyrotoxicosis","volume":"26","author":"Martino","year":"1985","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"10.1016\/j.lpm.2018.09.001_bib0600","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/jcem-63-2-485","article-title":"Uninhibited thyroidal uptake of radioiodine despite iodine excess in amiodarone-induced hypothyroidism","volume":"63","author":"Wiersinga","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0605","doi-asserted-by":"crossref","first-page":"20160836","DOI":"10.1259\/bjr.20160836","article-title":"Evaluation of (99m)Tc-MIBI in thyroid gland imaging for the diagnosis of amiodarone-induced thyrotoxicosis","volume":"90","author":"Wang","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.lpm.2018.09.001_bib0610","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1530\/EJE-08-0348","article-title":"The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis","volume":"159","author":"Piga","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2018.09.001_bib0615","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1210\/jc.2011-2390","article-title":"Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial","volume":"97","author":"Eskes","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0620","first-page":"2930","article-title":"Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study","volume":"81","author":"Bartalena","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0625","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40618-015-0426-0","article-title":"The presence of anti-thyroglobulin (TgAb) and\/or anti-thyroperoxidase antibodies (TPOAb) does not exclude the diagnosis of type 2\u00a0amiodarone-induced thyrotoxicosis","volume":"39","author":"Tomisti","year":"2016","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.lpm.2018.09.001_bib0630","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00002018-200629030-00006","article-title":"Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis","volume":"29","author":"Uzan","year":"2006","journal-title":"Drug Saf Int J Med Toxicol Drug Exp"},{"key":"10.1016\/j.lpm.2018.09.001_bib0635","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1210\/jc.2009-0940","article-title":"Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study","volume":"94","author":"Bogazzi","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0640","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/105072504322880391","article-title":"Can amiodarone be restarted after amiodarone-induced thyrotoxicosis?","volume":"14","author":"Ryan","year":"2004","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.lpm.2018.09.001_bib0645","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archinte.1993.00410070068010","article-title":"Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid","volume":"153","author":"Roti","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.lpm.2018.09.001_bib0650","first-page":"1273","article-title":"Iodine-induced subclinical hypothyroidism in euthyroid subjects with a previous episode of amiodarone-induced thyrotoxicosis","volume":"75","author":"Roti","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0655","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1046\/j.1445-5994.2003.00463.x","article-title":"Heterogeneity of amiodarone-induced thyrotoxicosis: evaluation of colour-flow Doppler sonography in predicting therapeutic response","volume":"33","author":"Wong","year":"2003","journal-title":"Intern Med J"},{"key":"10.1016\/j.lpm.2018.09.001_bib0660","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-17-0018","article-title":"The Clinical value of regular thyroid function tests during amiodarone treatment","author":"Benjamens","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2018.09.001_bib0665","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1089\/thy.2016.0229","article-title":"2016\u00a0American thyroid association guidelines for giagnosis and management of hyperthyroidism and other causes of thyrotoxicosis","volume":"26","author":"Ross","year":"2016","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"10.1016\/j.lpm.2018.09.001_bib0670","first-page":"1153","article-title":"Cardiac consequences of clinical dysthyroidism. Pathophysiological, clinical, and epidemiologic data","volume":"34","author":"Vinzio","year":"2005","journal-title":"Presse Medicale Paris Fr 1983"},{"key":"10.1016\/j.lpm.2018.09.001_bib0675","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-08-0553","article-title":"Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis?","volume":"159","author":"Tanda","year":"2008","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"key":"10.1016\/j.lpm.2018.09.001_bib0680","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4158\/EP.17.3.456","article-title":"Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists","volume":"17","author":"Bahn","year":"2011","journal-title":"Endocr Pract"},{"key":"10.1016\/j.lpm.2018.09.001_bib0685","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2265.2006.02590.x","article-title":"Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey","volume":"65","author":"Diehl","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2018.09.001_bib0690","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF03348098","article-title":"Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole","volume":"9","author":"Martino","year":"1986","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.lpm.2018.09.001_bib0695","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1136\/bmj.298.6687.1547","article-title":"Treatment of amiodarone induced hyperthyroidism with potassium perchlorate and methimazole during amiodarone treatment","volume":"298","author":"Reichert","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2018.09.001_bib0700","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1210\/jc.2012-1797","article-title":"Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction","volume":"97","author":"Tomisti","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0705","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.beem.2009.07.001","article-title":"Amiodarone and thyroid","volume":"23","author":"Eskes","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0710","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00268-005-0673-x","article-title":"Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease","volume":"30","author":"Gough","year":"2006","journal-title":"World J Surg"},{"key":"10.1016\/j.lpm.2018.09.001_bib0715","first-page":"45","article-title":"Total Thyroidectomy for Amiodarone-induced Thyrotoxicosis in the Hyperthyroid State","volume":"124","author":"Kaderli","year":"2016","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.lpm.2018.09.001_bib0720","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/0310057X0102900104","article-title":"Anaesthesia for amiodarone-induced thyrotoxicosis: a case review","volume":"29","author":"Sutherland","year":"2001","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.lpm.2018.09.001_bib0725","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/PL00024613","article-title":"Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective?","volume":"22","author":"Hamoir","year":"1998","journal-title":"World J Surg"},{"key":"10.1016\/j.lpm.2018.09.001_bib0730","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00268-004-7599-6","article-title":"Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience","volume":"28","author":"Houghton","year":"2004","journal-title":"World J Surg"},{"key":"10.1016\/j.lpm.2018.09.001_bib0735","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jca.21309","article-title":"Preoperative therapeutic apheresis for severe medically refractory amiodarone-induced thyrotoxicosis: a case report","volume":"29","author":"Yamamoto","year":"2014","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.lpm.2018.09.001_bib0740","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1017\/S0022215112000722","article-title":"Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation?","volume":"126","author":"Pierret","year":"2012","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.lpm.2018.09.001_bib0745","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1444-0903.2004.00600.x","article-title":"Plasmapheresis as a potential treatment option for amiodarone-induced thyrotoxicosis","volume":"34","author":"Diamond","year":"2004","journal-title":"Intern Med J"},{"key":"10.1016\/j.lpm.2018.09.001_bib0750","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jca.20200","article-title":"Preoperative therapeutic plasma exchange in patients with thyrotoxicosis","volume":"24","author":"Ezer","year":"2009","journal-title":"J Clin Apheresis"},{"key":"10.1016\/j.lpm.2018.09.001_bib0755","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7326\/0003-4819-131-1-199907060-00023","article-title":"Plasmapheresis in thyrotoxicosis","volume":"131","author":"Ligtenberg","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2018.09.001_bib0760","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1365-2265.2008.03405.x","article-title":"Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1\u00a0amiodarone-induced thyrotoxicosis (AIT)","volume":"70","author":"Albino","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2018.09.001_bib0765","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2265.2004.02134.x","article-title":"The effects of recombinant human thyrotropin, in normal subjects and patients with goitre","volume":"61","author":"Nielsen","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2018.09.001_bib0770","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2265.2009.03600.x","article-title":"Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1\u00a0amiodarone-induced thyrotoxicosis: a cautionary note","volume":"72","author":"Bogazzi","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2018.09.001_bib0775","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/ncpendmet0592","article-title":"Treatment of amiodarone-associated thyrotoxicosis","volume":"3","author":"Franklyn","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.lpm.2018.09.001_bib0390","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4158\/EP13059.OR","article-title":"Amiodarone-induced thyrotoxicosis in adults with congenital heart disease--clinical presentation and response to therapy","volume":"20","author":"Stan","year":"2014","journal-title":"Endocrinol Pract"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075549821830335X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075549821830335X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T21:51:20Z","timestamp":1720648280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075549821830335X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S075549821830335X"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2018.09.001","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enjeux li\u00e9s \u00e0 l\u2019hyperthyro\u00efdie induite par l\u2019amiodarone","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2018.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}